Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Atrial fibrillation: Apixaban cost-effective in the long term?

Nature Reviews Cardiology volume 9, page 492 (2012)Cite this article

Subjects

The costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness of apixaban vs aspirin have been assessed for patients with atrial fibrillation who are unsuitable for warfarin. In a 1-year model, apixaban was found to be more costly than aspirin ($3,545 vs $1,805 per patient) and associated with the same QALYs (0.96 for both). In a 10-year model, however, apixaban was found to be less costly than aspirin ($44,232 vs $50,066 per patient) and associated with somewhat higher QALYs (6.87 vs 6.51). Apixaban was determined to be a cost-effective alternative to aspirin 96.7% of the time in the 10-year model.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Lee, S. et al. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ. Cardiovasc. Qual. Outcomes doi: 10.1161/CIRCOUTCOMES.112.965251

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atrial fibrillation: Apixaban cost-effective in the long term?. Nat Rev Cardiol 9, 492 (2012). https://doi.org/10.1038/nrcardio.2012.105

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2012.105

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing